EICHOR
● Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
Condition: Type 2 Diabetes · Sponsor: Eli Lilly and Company
About this study
The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.
This description comes directly from the study's public registry record.
Talk to the study team
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact · clinical_inquiry_hub@lilly.com
Always discuss trial participation with your own doctor first.
Locations (51)
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| Arkansas Childrens Hospital | Little Rock, Arkansas, United States | Recruiting |
| Division of Endocrinology, Diabetes, and Metabolism | Los Angeles, California, United States | Recruiting |
| UCLA Mattel Children's Hospital | Los Angeles, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Children's Hospital of Colorado | Denver, Colorado, United States | Not Yet Recruiting |
| Yale Diabetes Research | New Haven, Connecticut, United States | Recruiting |
| Emerson Clinical Research Institute | Washington D.C., District of Columbia, United States | Recruiting |
| Children's National Medical Center | Washington D.C., District of Columbia, United States | Not Yet Recruiting |
| Nemours Children's Health | Jacksonville, Florida, United States | Recruiting |
| D&H National Research Centers, Inc | Miami, Florida, United States | Recruiting |
| AdventHealth Orlando | Orlando, Florida, United States | Recruiting |
+ 39 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06739122